Previous 10 | Next 10 |
Big-cap stocks are generally solid investments, but not all deliver the best returns. Sometimes small-cap stocks are better performers and reward investors with enormous gains. The TSX has a wide selection of potential multi-baggers. Among the names you should keep an eye on are Aura ...
TORONTO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at H.C. Wainwright’s 2nd Annual Psychedelics Con...
Psychedelic substances like MDMA and psilocybin show great potential in treating patients with neurological or psychiatric problems. Therefore, drug development companies are showing an increasing interest in the field. Given the industry’s growth potential, Wall Street analysts expect...
The following slide deck was published by Field Trip Health Ltd. in conjunction with this event. For further details see: Field Trip Health (FTRP) Investor Presentation - Slideshow
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelic drugs could be a major game-changer when it comes to treating mental illness, so loading up on some psychedelic stocks only makes sense. All as psilocybin, LSD, MDMA, and mescaline for example show progress in...
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and t...
Field Trip Health Ltd. (FTRP) Q2 2022 Earnings Conference Call November 16, 2021 8:30 A.M. ET Company Participants Kathleen Heaney - KCSA Strategic Communications Joseph del Moral - Co-Founder and Chief Executive Officer Ronan Levy - Co-Founder and Executive Chairman Donna Wong - Chief Financ...
After the market closed on Monday, Field Trip Health Ltd. (NASDAQ: FTRP) reported its second fiscal quarter 2022 results for the second fiscal quarter ending September 30, 2021, and provided a business update. Field Trip earned patient services revenues of $907,816 from ...
Field Trip Health (NASDAQ:FTRP): FQ2 GAAP EPS of -C$0.23. Revenue of C$0.91M (+911.1% Y/Y) Press Release For further details see: Field Trip Health reports FQ2 results
Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications. Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk pro...
News, Short Squeeze, Breakout and More Instantly...
Field Trip Health Ltd. Company Name:
FTRP Stock Symbol:
NASDAQ Market:
TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (formerly, Field Trip Health Ltd., the " Company " or “ Reunion ”), a global leader in the discovery and development of innovative of psychedelic-inspired therapeutics for improved mental health outco...
Field Trip Health has changed its name to Reunion Neuroscience Inc. (TSX: FTRP)(Nasdaq: FTRP) and reported its fiscal first quarter 2023 results for the period ending June 30, 2022. Reunion reported expenses of $5 million and a net loss of $13 million. The increase in net loss...
Completed corporate reorganization, separating the Field Trip Discovery and Field Trip Health divisions into two separate companies. Field Trip Discovery renamed Reunion Neuroscience Inc. (“ Reunion ” or the “ Company ”), and will remain listed on t...